Precision Biosciences Stock Price, News & Analysis

iECURE (DTIL) announced that the FDA granted RMAT designation to ECUR-506 for neonatal onset ornithine transcarbamylase (OTC) deficiency, enabling intensified FDA interaction and expedited review.

The company said it aligned with the FDA on primary and key secondary endpoints, comparators, and sample size for the ongoing OTC-HOPE study, which could support a Biologics License Application (BLA). ECUR-506 also received an Innovation Passport under the UK’s relaunched ILAP. iECURE reported a complete clinical response in the first infant treated in OTC-HOPE and holds prior Rare Pediatric Disease and Orphan Drug designations.

Precision BioSciences (Nasdaq: DTIL) announced that on Dec 9, 2025 its Compensation Committee approved an inducement award of 8,224 restricted stock units (RSUs) for a newly hired employee under the company's 2021 Employment Inducement Incentive Award Plan.

The RSUs were granted under Nasdaq Listing Rule 5635(c)(4) as an inducement to commence employment and vest in substantially equal annual installments on each of the first three anniversaries of the employee's start date, subject to continued service.

Precision BioSciences (Nasdaq: DTIL) will present clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV at Hep-DART 2025 in Honolulu, December 7–11, 2025.

The oral presentation titled “PBGENE-HBV, a first-in-class gene editing therapy for chronic hepatitis B, demonstrates safety and antiviral activity across three cohorts” is scheduled for Tuesday, December 9, 4:45pm HST and will be presented by Man-Fung Yuen, MBBS, MD, PhD, DSc, with authorship including Cassandra L. Gorsuch and others.

The announcement emphasizes Phase 1 clinical results on safety and antiviral activity for an in vivo ARCUS® gene editing candidate targeting viral templates that drive chronic hepatitis B.

Precision BioSciences (Nasdaq: DTIL) announced an underwritten offering expected to raise approximately $75 million in gross proceeds by selling 10,815,000 common shares, pre-funded warrants to purchase 1,400,000 shares and accompanying warrants.

The per-unit price is $6.14 (pre-funded at $6.139995); each whole warrant has a $7.25 exercise price, is exercisable immediately and expires five years after issuance. The offering is expected to close on or about November 12, 2025, and proceeds will fund R&D, working capital and general corporate purposes.

Precision BioSciences (Nasdaq: DTIL) reported late-breaking Phase 1 ELIMINATE-B data for PBGENE-HBV on November 10, 2025 showing repeat administrations (0.2, 0.4, 0.8 mg/kg) were well tolerated with no dose-limiting toxicities through a 10/31/2025 cutoff.

Across 9 patients and 22 doses, all treated participants showed measurable, dose-dependent declines in HBsAg (reductions up to 66% in Cohort 2 and a reported 64% deepening response after two doses in Cohort 3). A paired liver biopsy demonstrated ARCUS-mediated HBV DNA editing. Company expects to complete Cohort 3 dosing in Q1 2026 and to test nucleos(t)ide withdrawal if HBsAg becomes undetectable or sustainably low.

Precision BioSciences (NASDAQ: DTIL) reported Q3 2025 results and a program update. As of September 30, 2025, the company held $71.2 million in cash and expects a cash runway into the second half of 2027. Q3 results included total revenue <$0.1M, R&D of $13.4M, G&A of $7.3M, and a net loss of $21.8M (‑$1.84/share).

Clinical highlights: PBGENE-HBV advanced with dosing in Cohort 3 and a late‑breaking AASLD oral presentation on November 10, 2025; Phase 1 ELIMINATE‑B showed tolerability and one Cohort 1 patient with ~50% durable HBsAg reduction at seven months. PBGENE‑DMD IND filing is anticipated by end of 2025, with Phase 1 start in H1 2026 and initial data in H2 2026. A U.S. patent covering the HBV ARCUS nuclease expires March 2042. Imugene milestone payment of $8M received Oct 31, 2025.

Precision BioSciences (Nasdaq: DTIL) said it will publish its third quarter 2025 financial results and provide a business update on November 3, 2025. The company is a clinical-stage gene editing firm using its proprietary ARCUS platform to develop in vivo therapies for high-unmet-need diseases.

Investors can expect a standard quarterly results release and a corporate update on programs and operations on that date.

Precision BioSciences (Nasdaq: DTIL) was selected for a late-breaking oral presentation at AASLD The Liver Meeting® 2025 in Washington, D.C., Nov 7-11, 2025.

The presentation will report new PBGENE-HBV data from the first two cohorts of the Phase 1 ELIMINATE-B Trial, describing safety and antiviral activity. Abstract title: "PBGENE-HBV, a First-in-class Gene Editing Therapy for Chronic Hepatitis B, Demonstrates Safety and Antiviral Activity in Early Cohorts." Publication number 5017. Presentation is scheduled for Monday, November 10, 2025, 5:30PM–6:00PM EST and lists multiple clinical authors.

Precision BioSciences (NASDAQ: DTIL) reported a peer‑reviewed publication in Nucleic Acids Research describing how its engineered ARCUS nucleases drive high‑efficiency homology‑directed gene insertion and diverse edits.

Key reported results include insertion efficiencies of 60–90% in dividing cells, 20–40% in non‑dividing cells, >85% transgene insertion in T lymphocytes, and up to 40% insertion in non‑dividing primary human hepatocytes. Mechanistic data attribute these rates to ARCUS‑generated 3′ overhangs that promote homology‑mediated repair. The publication highlights ARCUS applications across insertion, single‑base edits, deletions, and large DNA replacement relevant to the company’s in‑vivo programs (examples: ECUR‑506, PBGENE‑HBV, PBGENE‑DMD).